Patents by Inventor Edward Yin-Shiang Lin

Edward Yin-Shiang Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240083900
    Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 14, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Isaac Marx, Jürgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Edward Yin-Shiang Lin, Felix Gonzalez Lopez de Turiso, Thomas Purgett, Andrew George Capacci, Simone Sciabola
  • Publication number: 20230117898
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: August 24, 2022
    Publication date: April 20, 2023
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20230113598
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 13, 2023
    Inventors: Joseph ARNDT, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cheng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt Van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • Patent number: 11465963
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 11, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • Patent number: 11459324
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220259197
    Abstract: Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical comositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, and Z are as defined herein.
    Type: Application
    Filed: March 6, 2020
    Publication date: August 18, 2022
    Applicant: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220106305
    Abstract: Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.
    Type: Application
    Filed: February 3, 2020
    Publication date: April 7, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220048884
    Abstract: Provided are compounds of Formula A or I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 17, 2022
    Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin Shiang Lin, Brian Stuart Lucas, Bin Ma
  • Publication number: 20220041586
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 10, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20220017506
    Abstract: Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.
    Type: Application
    Filed: December 4, 2019
    Publication date: January 20, 2022
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20210387960
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 16, 2021
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • Publication number: 20210340107
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 4, 2021
    Inventors: Brian Stuart Lucas, Edward Yin Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • Patent number: 10968181
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: April 6, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian Stuart Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • Publication number: 20210070752
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Application
    Filed: June 18, 2020
    Publication date: March 11, 2021
    Inventors: Joseph ARNDT, Timothy R. CHAN, Kevin GUCKIAN, Gnanasambandam KUMARAVEL, Wen-Cherng LEE, Edward Yin-Shiang LIN, Daniel SCOTT, Lihong SUN, Jermaine THOMAS, Kurt VAN VLOTEN, Deping WANG, Lei ZHANG, Daniel ERLANSON
  • Publication number: 20210040080
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Patent number: 10894040
    Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 19, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • Publication number: 20200299230
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 24, 2020
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • Publication number: 20200038385
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 6, 2020
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • Publication number: 20190389836
    Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin-Shiang Lin, Brian Stuart Lucas, Bin Ma
  • Publication number: 20190389830
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 26, 2019
    Inventors: Andrew George Capacci, Edward Yin-Shiang Lin, Brian Stuart Lucas